GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) - The U.S. Food and Drug Administration ...
The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...
GE HealthCare Technologies, Inc. GEHC announced that it has received FDA approval for Flyrcado (flurpiridaz F 18), a breakthrough positron emission tomography myocardial perfusion imaging (PET MPI) ...
CVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its mission to deliver the highest quality cardiovascular care for patients. CVAUSA ...
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results